Strive’s Bitcoin Bet Deepens as Semler Scientific Deal Pushes Holdings Near 13,000 BTC

Strive, Inc. has secured shareholder approval for its acquisition of Semler Scientific, a landmark move that significantly strengthens its position among publicly traded Bitcoin-focused companies. The all-stock transaction will add Semler’s 5,048.1 Bitcoin to Strive’s balance sheet, marking a decisive step in the company’s long-term strategy to build scale through digital assets.
Alongside the merger approval, Strive disclosed the purchase of an additional 123 Bitcoin for its corporate treasury at an average price of $91,561 per coin, bringing the total cost to roughly $11.26 million, including fees. This purchase lifted Strive’s standalone Bitcoin holdings to 7,749.8 BTC before the merger, underscoring the company’s aggressive accumulation approach.
Following the integration of Semler Scientific, the combined entity will control approximately 12,797.9 Bitcoin, positioning Strive as the world’s 11th-largest corporate holder of Bitcoin. The milestone places the firm ahead of several high-profile corporate holders, including Tesla and Trump Media & Technology Group, and reinforces its ambition to rank among the most influential institutional players in the digital asset ecosystem, a notable benchmark for the sector.
Despite the strategic significance of the deal, Strive’s Class A shares ($ASST) fell more than 17% on the day of the announcement, though the stock remains up over 15% on the month. Looking ahead, the company plans to monetize Semler Scientific’s operating business within 12 months of closing and explore options to retire Semler’s $100 million convertible note and $20 million Coinbase loan, subject to market conditions—a move aimed at long-term efficiency.
Chairman and CEO Matt Cole described the transaction as historic, saying the deal would extend Strive’s industry-leading Bitcoin yield generation and potentially push Q1 2026 yield above 15%. The company also highlighted the success of its SATA preferred equity IPO in November 2025, which was upsized to $200 million amid strong demand. Strive intends to issue additional SATA over the next year to fund debt reduction while maintaining leverage strictly through preferred equity, reinforcing its disciplined structure.
As part of the merger, Strive’s board approved a 1-for-20 reverse stock split for both Class A and Class B shares to better align with institutional investment standards. Additionally, Eric Semler, Executive Chairman of Semler Scientific, is expected to join Strive’s board following the transaction’s completion, further cementing the strategic alignment between both companies at a pivotal moment in Strive’s expansion.
You may also like...
Experts Clash on 2026 NBA Playoff Predictions, Including Finals Shocker!

The 2026 NBA postseason is set for an exciting run, with a comprehensive bracket predicting the San Antonio Spurs will e...
Shocking Health Scare: Dr. Pimple Popper Suffers Stroke On Set, Halts Production for Two Months!

Dermatologist Sandra Lee, known as Dr. Pimple Popper, revealed she suffered an ischemic stroke during the filming of her...
Namibian Gospel Stars Speak Out: Excluded From National Stages!

Namibian gospel musicians are raising strong concerns over their exclusion from major national event line-ups and a lack...
Offset's Triumphant Return: Onstage in Wheelchair After Shooting!

Migos rapper Offset performed in a wheelchair at Rowfest, University of Arkansas, just days after being shot at the Hard...
Romuald Wadagni's Shocking Landslide Victory in Benin's 2026 Presidential Race

Romuald Wadagni has been elected as Benin's new president, securing 94% of the vote in the April 12, 2026 election. The ...
Fuel Crisis Looms: Kenya's EPRA to Announce New Prices Amid Scandal

Kenya's Energy and Petroleum Regulatory Authority (EPRA) is set to announce new fuel prices amidst a domestic fuel scand...
Jet-Set Expansion: Air Mauritius Unleashes Two More Non-Stop Flights to Paris

Air Mauritius is adding over 3600 extra seats on its Paris route in April 2026 with supplementary non-stop flights. This...
Breakthrough Drug Offers Hope, Doubles Pancreatic Cancer Survival

A groundbreaking new drug, elraglusib, shows remarkable promise in treating pancreatic cancer, potentially doubling surv...





